Jeffry Adiwidjaja, Ph.D.
Scientist II
Physiologically Based Pharmacokinetics (PBPK) Solutions
About Jeffry
Dr. Adiwidjaja is a Scientist II on the Simulation Studies team at Simulations Plus, Inc. He received his Bachelor of Pharmacy and a Master’s degree from Bandung Institute of Technology in Indonesia. After receiving his Ph.D. at Sydney Pharmacy School, the University of Sydney, Australia, he spent a period at the University of North Carolina at Chapel Hill, USA to undertake postdoctoral training in collaboration with Simulations Plus, Inc. and the DILIsym Division. His Ph.D. research focused on understanding interindividual variability on pharmacokinetics and responses to anti-cancer drugs using modeling and simulation, and how best to implement such understanding to improve cancer therapy. Throughout the Ph.D. candidature and postdoctoral fellowship, Dr. Adiwidjaja has honed his skills in pharmacokinetic and pharmacodynamic modeling and simulation, particularly using the physiologically based pharmacokinetic (PBPK) approach and has developed fundamental skills in, in vitro drug metabolism and interactions.
During his academic training, Dr. Adiwidjaja successfully secured a postgraduate scholarship from the Indonesian government and several travel grants, and received several scientific recognitions, including best oral presenter at the APSA-ASCEPT Joint Meeting (2017, Australia), runner-up of the Simcyp Academic Award for the most informative scientific report (2020), and finalist for best poster presenter at the ISSX-MDO Meeting (2020, USA). He has published more than a dozen of peer-reviewed articles, reviews, and book chapters; primarily in the area of pharmacokinetics, natural product-drug interactions, and implementation of PBPK modeling and simulation to provide mechanistic insights into drug interactions and to help guide drug dosing in special patient populations (e.g., pediatrics and patients with nonalcoholic fatty liver disease).
His long-term goals are to become an expert in mathematical modeling of drug pharmacokinetics, safety, and efficacy, and to contribute to research projects that have a direct impact in the clinical setting or from a regulatory standpoint. This was exactly what drove him to join Simulations Plus, Inc. in early 2023. He looks forward to the many opportunities Simulations Plus, Inc. has to offer and to growing mentally and professionally with the company. In his spare time, he enjoys watching movies and spending quality time with his family.
